Skip Navigation
Menu
ACP Journal Club |15 December 2015

Review: Combination umeclidinium/vilanterol improved health status more than umeclidinium in COPD

Matthew B. Stanbrook, MD, PhD

Article, Author, and Disclosure Information
FULL TEXT
Rodrigo GJ, Neffen H. A systematic review of the efficacy and safety of a fixed-dose combination of umeclidinium and vilanterol for the treatment of COPD. Chest. 2015;148:397-407. 25798635

GIM/FP/GP:

Pulmonology:

In adults with chronic obstructive pulmonary disease (COPD), what are the relative efficacy and safety of combination umeclidinium/vilanterol (UMEC/VIL) and its monocomponents, tiotropium, or fluticasone propionate/salmeterol (FSC)?
Included studies compared UMEC/VIL with UMEC, VIL, tiotropium, or FSC in adults ≥ 40 years of age who had stable moderate to very severe COPD and reported a relevant outcome. Outcomes included health status (St. George's Respiratory Questionnaire total score, minimal clinically important...
FULL TEXT
PDF
Not Available
Citations
Citation

Stanbrook MB. Review: Combination umeclidinium/vilanterol improved health status more than umeclidinium in COPD. Ann Intern Med. 2015;163:JC10. doi: 10.7326/ACPJC-2015-163-12-010

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2015;163(12):JC10.

DOI: 10.7326/ACPJC-2015-163-12-010

0 Citations

Related Articles
Health Values of the Seriously Ill
Annals of Internal Medicine; 122 (7): 514-520
In symptomatic COPD, once-daily triple vs dual therapy reduced moderate or severe exacerbations at 1 year
Annals of Internal Medicine; 169 (4): JC16
In COPD, long-term use of higher doses of inhaled corticosteroids was linked to increased fracture risk
Annals of Internal Medicine; 168 (12): JC71
In COPD, new use of long-acting bronchodilators was linked to CV events at ≤ 30 days, but not > 30 days
Annals of Internal Medicine; 168 (8): JC47
View MoreView Less

Journal Club
In symptomatic COPD, once-daily triple vs dual therapy reduced moderate or severe exacerbations at 1 year
Annals of Internal Medicine; 169 (4): JC16
In COPD, long-term use of higher doses of inhaled corticosteroids was linked to increased fracture risk
Annals of Internal Medicine; 168 (12): JC71
In COPD, new use of long-acting bronchodilators was linked to CV events at ≤ 30 days, but not > 30 days
Annals of Internal Medicine; 168 (8): JC47
In smokers with COPD, neither varenicline nor bupropion was linked to increased CV or neuropsychiatric risk vs NRT
Annals of Internal Medicine; 167 (6): JC31
View MoreView Less

Related Point of Care
Chronic Obstructive Pulmonary Disease
Annals of Internal Medicine; 154 (7): ITC4-1
Chronic Obstructive Pulmonary Disease
Annals of Internal Medicine; 148 (5): ITC3-1
View MoreView Less

Related Topics
Chronic Obstructive Airway Disease
Pulmonary/Critical Care

Chronic Obstructive Airway Disease, Pulmonary/Critical Care.

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×